JPMorgan analyst Anupam Rama lowered the firm’s price target on Vera Therapeutics to $22 from $25 and keeps an Overweight rating on the shares. The analyst updated models in the SMid cap biotechnology group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERA:
- Vera Therapeutics upgraded to Buy from Hold at Jefferies
- Vera Therapeutics reports Q3 EPS (45c), consensus (54c)
- Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
- Vera Therapeutics presents data from Phase 2b ORIGIN study
- Vera Therapeutics presents ‘positive’ atacicept data from Phase 2b ORIGIN study